Rigel Pharmaceuticals Inc represents values of innovation, integrity, and patient-centeredness in its corporate philosophy. With a focus on discovering, developing, and commercializing novel treatments, Rigel Pharmaceuticals Inc strives to improve the lives of patients with unmet medical needs. The company's dedication to scientific excellence and commitment to delivering safe and effective therapies is reflected in its ongoing efforts. Rigel Pharmaceuticals Inc continues to leverage its expertise and advanced technologies to address various diseases and provide hope for patients worldwide.

Rigel Pharmaceuticals Inc is primarily present in the United States.

Rigel Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for TAVALISSE® (fostamatinib disodium hexahydrate) tablets, indicated for the treatment of chronic immune thrombocytopenia (ITP). Moreover, Rigel received marketing approval for TAVALISSE in the European Union, providing access to a broader patient population. The company has also made progress in the clinical development of its pipeline products, including R835, an investigational treatment for autoimmune and inflammatory diseases. Additionally, Rigel entered into strategic collaborations with partners such as Grifols and Kissei Pharmaceutical Co., Ltd., enhancing its research and commercial capabilities. These achievements demonstrate Rigel Pharmaceuticals Inc's commitment to advancing innovative therapies for various medical conditions.

Rigel Pharmaceuticals Inc is a biotechnology company specializing in the discovery and development of innovative small-molecule drugs. Founded in 1996, Rigel focuses on creating novel therapies to improve the lives of patients with immune and hematological disorders, cancer, and rare diseases. The company is committed to advancing scientific research and has built a strong pipeline of potential treatments. With a dedicated team of scientists and researchers, Rigel Pharmaceuticals Inc strives to make a meaningful impact in the field of medicine, bringing hope and improved health outcomes to patients worldwide.

The main competitors of Rigel Pharmaceuticals Inc in the market include companies such as Intercept Pharmaceuticals Inc, Gilead Sciences Inc, and Novartis AG. These competitors also operate in the biotechnology and pharmaceutical industry, offering similar products and services. Rigel Pharmaceuticals Inc faces competition in the development and commercialization of innovative drugs and therapeutic solutions within this competitive landscape.

Rigel Pharmaceuticals Inc primarily operates in the biotechnology and pharmaceutical industries.

Rigel Pharmaceuticals Inc is a biotechnology company focused on the discovery, development, and commercialization of novel small molecule drugs. Its business model revolves around developing innovative therapeutics to treat immunology and oncology diseases. With a particular emphasis on targeted protein degradation, Rigel Pharmaceuticals aims to bring life-changing medicines to patients in need. By leveraging its expertise in cellular signaling pathways, the company strives to provide effective and targeted therapies that can address unmet medical needs. Through strategic collaborations and internal research programs, Rigel Pharmaceuticals Inc remains committed to advancing scientific knowledge and improving patient outcomes.

De Rigel Pharmaceuticals K/W is -114,95.

De Rigel Pharmaceuticals KUV is 12,12.

De AlleAktien Kwaliteitsscore voor Rigel Pharmaceuticals is 4/10.

De verwachte Rigel Pharmaceuticals omzet is 152,10 mln. USD.

De verwachte Rigel Pharmaceuticals winst is -16,03 mln. USD.

Rigel Pharmaceuticals Inc is a biotechnology company that specializes in the development of drugs for the treatment of serious diseases. The company focuses on the development of prescription drugs that affect the immune system and metabolism. Rigel Pharmaceuticals' business model is based on three main divisions: research and development, sales and marketing, and clinical studies. The company's research and development focuses on identifying and developing new drugs, as well as improving existing drugs. The company utilizes a combination of independent research and collaboration with other companies and institutions. The production and manufacturing costs of the drugs are largely financed through sales revenue. Rigel Pharmaceuticals' sales and marketing department is responsible for marketing and selling the drugs. The company relies on close collaboration with doctors, hospitals, and other healthcare facilities. Customer information and marketing activities are optimized to reach the desired target audience and increase the company's visibility and product awareness. The clinical studies conducted by Rigel Pharmaceuticals play a crucial role in the business model, as they demonstrate the potential of new drugs and ensure their safety and effectiveness. These studies involve testing drugs on different patient groups to determine their effects and safety. While these studies are time-consuming and costly, they are necessary to meet regulatory requirements. Rigel Pharmaceuticals' portfolio currently includes several products that focus on different areas of medicine. The company currently focuses on drugs that can be used in immune-related diseases, such as arthritic inflammation. This includes Fostamatinib, the first FDA-approved drug for rheumatoid arthritis. The company also focuses on the discovery of new molecules and technological innovations that contribute to the development of new drugs. Overall, Rigel Pharmaceuticals' business model is based on the development of drugs and effective marketing and sales of these drugs. The company utilizes advanced technologies and methods in research and clinical studies, allowing it to provide innovative solutions for today's and tomorrow's medical challenges.

Rigel Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Rigel Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Rigel Pharmaceuticals is US7665596034.

Het WKN van Rigel Pharmaceuticals is 766093.

De ticker van Rigel Pharmaceuticals is RIGL.

Binnen de laatste 12 maanden betaalde Rigel Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Rigel Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Rigel Pharmaceuticals is momenteel .

Rigel Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Rigel Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Rigel Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Rigel Pharmaceuticals van 16-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 16-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 16-7-2024.

In het jaar 2023 heeft Rigel Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Rigel Pharmaceuticals worden in USD uitgekeerd.